tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Danimer Scientific sees FY23 adjusted EBITDA ($31M)-($23M)

Sees FY23 CapEx $26M-$31M. Michael Hajost, Danimer’s Chief Financial Officer, commented, "We are intently focused on revenue growth, which we expect to accelerate starting in our second quarter. As a result, we expect improving operating margins and operating cash flow as we move through the year."

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Published first on TheFly

See the top stocks recommended by analysts >>

Read More on DNMR:

Disclaimer & DisclosureReport an Issue

1